期刊文献+

氯沙坦对进展性肾炎模型大鼠肾小管-间质细胞巨噬细胞移动抑制因子的影响研究 被引量:1

Effects of Losartan on MIF in Tubulointerstitial Cells in Progressive Nephritis Model Rats
原文传递
导出
摘要 目的:探讨氯沙坦对进展性肾炎模型大鼠肾小管-间质细胞巨噬细胞移动抑制因子(MIF)的影响。方法:取大鼠行右肾切除并注射鼠单克隆IgG(OX-7)抗Thy1.1抗体2次建立进展性肾炎大鼠模型,于第4周时取部分大鼠立即处死作为模型组,将剩余模型大鼠分为对照组和氯沙坦高、低剂量组(80、20mg.kg-1.d-1),再另取大鼠行假手术作为假手术组,每组5只,各组灌胃给予相应药物连续4周,观察各组大鼠肾小管-间质细胞中MIF、巨噬细胞标记抗原ED-1的表达及肾组织病理变化。结果:与假手术组比较,模型组大鼠肾小管-间质细胞中MIF、ED-1表达明显升高(P<0.001);与对照组比较,氯沙坦高、低剂量组MIF、ED-1表达明显降低(P<0.01或P<0.001)。病理观察发现,模型组大鼠肾小管-间质受损,而氯沙坦高、低剂量组肾小管-间质的损伤均有改善。结论:氯沙坦可能通过降低进展性肾炎模型大鼠MIF和ED-1的表达来发挥抑制肾小管-间质细胞炎症反应的作用。 OBJECTIVE: To investigate the effects of losartan on macrophage migration inhibitory factor (MIF) in tubulointerstitial cells in progressive nephritis model rats. METHODS: Rats were selected and underwent right nephrectomy and injected IgG (OX-7) mouse monoclonal anti-Thy1.1 antibody twice, and progressive nephritis model was established. Some rats were sacrificed at 4th week as model group, and other rats were divided into control group and losartan high-dose and low-dose groups (80, 20 mg.kg-1.d-1) with 5 rats in each group. Other rats were selected as sham operation group. Relevant drugs were irrigated into the stomachs of the rats for 4 weeks in all groups. The expression of MIF and macrophage marker antigen ED-1, and the tubulointersti- tial pathological changes were examined. RESULTS: Compared with sham operation group, the expression of MIF and ED-1 in- creased significantly in model group (P〈0.001); compared with control group, the expression of MIF and ED-1 decreased significantly in losartan high-dose and low-dose groups (P〈0.01 or P〈0.001). Pathological observation indicated that tubulointerstitial injury was found in model group, and tubulointerstitial injury was ameliorated in losartan high-dose and low-dose groups. CONCLUSION: Losartan may ameliorate the progression of tubulointerstitial inflammation by intervene the expression of MIF and ED-1 in the progressive nephritis model rat.
出处 《中国药房》 CAS CSCD 北大核心 2011年第33期3098-3100,共3页 China Pharmacy
基金 贵州省优秀科技教育人才省长专项资金项目(黔省专合字(2010)89号) 贵州省"十一五"社会发展科技项目(黔科合SY字[2008]3058)
关键词 氯沙坦 进展性肾炎 大鼠 巨噬细胞移动抑制因子 巨噬细胞标记抗原ED-1 Logartan Progressive nephritis Rats Macrophage migration inhibitory factor Macrophage marker antigen ED-1
  • 相关文献

参考文献8

二级参考文献30

  • 1陈凌,游晓华,潘静薇,秦永文,毕文杉,郑兴.替米沙坦治疗轻中度高血压患者降压效果及其安全性[J].药学服务与研究,2005,5(1):35-37. 被引量:8
  • 2杨娟,郑青山.Meta分析的统计学方法[J].中国临床药理学与治疗学,2005,10(11):1309-1314. 被引量:58
  • 3屈虎,何伟玺,何冉.替米沙坦治疗122例高血压临床对照研究[J].临床心身疾病杂志,2006,12(2):115-116. 被引量:2
  • 4Fine LG, Orphanides C. Progressive renal disease: the chronic hypoxia hypothesis[J]. Kidney lnt, 1998, 53 (sup- pl 65): S74.
  • 5Matsumoto M. Hypoperfusion ofperitubular capillaries in- duces chronic hypoxia before progression of tubulointer- stitial injury in a progressive model of rat glomerulone- phritis[J]. JAm Soc Nephrol, 2004,15(6) : 1 574.
  • 6Norman JT, Clark IM. Hypoxia promotes fibrogenesis in human renal fibroblasts[J]. Kidney Int, 2008,58 (6) : 2 351.
  • 7Higgins DF, Bijiu MP. Hypoxic induction of TGF-13 is dir- ectly mediated by Hif-l[J]. Am J Physiol Renal Physiol, 2004,287(6) :F1 223.
  • 8Fyhrquist F, Saijonmaa O. Renin-angiotensin system revis- ited[J]. Jlntern Med, 2008,264(3) : 224.
  • 9Klahr S. Obstructive nephropathy[J]. Jlntern Med, 2007, 259(3):355.
  • 10Manotham K, Tanaka T, Matsumoto M, et al. Evidence of tubular hypoxia in the early phase in the progressive ne- phritis model[J]. JAm Soc Nephrol, 2004,15(5) : 1 277.

共引文献15

同被引文献19

  • 1McClellan AC ,Plantinga L,McClellan WM.Epidemiology, geography and chronic kidney disease[J].Curr Opin Nephrol Hypertens, 2012,21 (3) : 323 -328.
  • 2Matsumoto K, Maruyama T.Elevated macrophage migration inhibitiory factor (MIF)levels in the urine of patients with focal glomerular sclerosi[J].Clin Exp Immunol,2005,139 (2) :338-347.
  • 3Sanchez-Nifio MD,Sanz AB,Ruiz-Andres O,et al.MIF, CD74 and other partners in kidney disease:tales of a promiscuous couple[J].Cytokine Growth Factor Rev,2013, 24(1) :23-40.
  • 4Nakima K, Tanaka Y, Nomiyama T, et al.RANTES promot- er genotype is associated with diabetic nephropathy in type 2 diabetic subjects[J].Diabetes Care, 2003,26 (3) : 892.
  • 5Lan A, Du J.Potential role of Akt signaling in chronic kid- ney disease[J].Nephrol Dial Transplant, 2014. [Epub ahead of print].
  • 6Mitchell R,Bacher M,Bernhagen J,et al.Cloning and char- acterization of the gene for mouse macrophage migration inhibitory factor (MIF)[J].J Immunol, 1995,154(8) :3863- 3870.
  • 7Asare Y,Schmitt M,Bemhagen J.The vascular biology of maerophage migration inhibitory factor (MIF).Expression and effects in inflammation,atherogenesis and angiogene- sis[J].Thromb Haemost, 2013,109 (3) : 391-398.
  • 8Bruchfeld A,Carrero JJ,Qureshi AR,et al.Elevated serum macrophage migration inhibitoryfactor(MIF)coneentrations in chronic kidney disease(CKD)are associated with mark- ers of oxidative stress and endothelial activation [J].Mol Meal,2009,15(3-4) :70-75.
  • 9Leng L,Chen L,Fan J,et al.A small-molecule maerophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 andMRIflpr mice[J].J Immunol, 2011,186( 1 ) : 527-538.
  • 10Wan F,Lenardo MJ.Specification of DNA binding activi- ty of NF-kappaB proteins[J].Cold Spring Harb Perspect Biol, 2009,1 (4) : a000067.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部